Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103975 | 0.98 | GABRA1 (0.70) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL10358563 | 0.96 | GABRA1 (0.67) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| Propofol SCHEMBL8026569 | 0.84 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| SCHEMBL14895142 | 0.83 | TSHR (0.48) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| SCHEMBL24440433 | 0.83 | GABRA1 (0.48) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| Propofol SCHEMBL2414429 | 0.81 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| Propofol SCHEMBL36245 | 0.81 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| SCHEMBL14895418 | 0.79 | LMNA (0.45) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| Propofol SCHEMBL4088686 | 0.79 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CYP3A4TSHR | |
| Propofol SCHEMBL8935177 | 0.79 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-4943666-A | Process for producing nitrophenol compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-07-24 | — | — | US | disclosed |
| EP-0339956-A1 | Process for producing nitrophenol compound | Takeda Chemical Industries, Ltd. (JP) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | SLC6A2 1045/4885GABRA1 4484/4885GABRB1 4368/4885 |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | SLC6A2 880/4885GABRA1 3227/4885GABRB1 3389/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | SLC6A2 753/4885GABRA1 4620/4885GABRB1 4433/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | SLC6A2 1387/4885GABRA1 4822/4885GABRB1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.